- Home
- NRIM vs RNAC Comparison
NRIM vs RNAC Comparison
Compare NRIM & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIM
- RNAC
- Stock Information
- Founded
- NRIM 1990
- RNAC 2007
- Country
- NRIM United States
- RNAC United States
- Employees
- NRIM N/A
- RNAC 66
- Industry
- NRIM Savings Institutions
- RNAC Biotechnology: Pharmaceutical Preparations
- Sector
- NRIM Finance
- RNAC Health Care
- Exchange
- NRIM Nasdaq
- RNAC Nasdaq
- Market Cap
- NRIM 514.9M
- RNAC 282.6M
- IPO Year
- NRIM N/A
- RNAC 2016
- Fundamental
- Price
- NRIM $97.04
- RNAC $13.24
- Analyst Decision
- NRIM
- RNAC Strong Buy
- Analyst Count
- NRIM 0
- RNAC 4
- Target Price
- NRIM N/A
- RNAC $40.67
- AVG Volume (30 Days)
- NRIM 67.6K
- RNAC 62.4K
- Earning Date
- NRIM 07-23-2025
- RNAC 08-07-2025
- Dividend Yield
- NRIM 2.62%
- RNAC N/A
- EPS Growth
- NRIM 46.48
- RNAC N/A
- EPS
- NRIM 7.52
- RNAC N/A
- Revenue
- NRIM $164,695,000.00
- RNAC $34,173,000.00
- Revenue This Year
- NRIM N/A
- RNAC N/A
- Revenue Next Year
- NRIM $7.05
- RNAC N/A
- P/E Ratio
- NRIM $13.01
- RNAC N/A
- Revenue Growth
- NRIM 26.35
- RNAC 31.91
- 52 Week Low
- NRIM $55.35
- RNAC $8.46
- 52 Week High
- NRIM $100.21
- RNAC $26.50
- Technical
- Relative Strength Index (RSI)
- NRIM 66.91
- RNAC 67.62
- Support Level
- NRIM $97.35
- RNAC $10.71
- Resistance Level
- NRIM $100.21
- RNAC $11.75
- Average True Range (ATR)
- NRIM 2.20
- RNAC 0.82
- MACD
- NRIM 0.53
- RNAC 0.23
- Stochastic Oscillator
- NRIM 81.39
- RNAC 91.66
About NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About RNAC Cartesian Therapeutics Inc.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.